Show Summary Details
Page of

Branched Stent Graft Placement in the Vena Cava Using the Endologix AFX 

Branched Stent Graft Placement in the Vena Cava Using the Endologix AFX
Chapter:
Branched Stent Graft Placement in the Vena Cava Using the Endologix AFX
Author(s):

S. Lowell Kahn

DOI:
10.1093/med/9780199986071.003.0031
Page of

PRINTED FROM OXFORD MEDICINE ONLINE (www.oxfordmedicine.com). © Oxford University Press, 2020. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 05 December 2020

Superior vena cava syndrome (SVCS) comprises a constellation of symptoms resulting from stenosis, occlusion, or thrombosis of the SVC of benign and malignant etiologies. The diagnosis is most commonly seen with thoracic malignancies, with primary lung cancer accounting for up to 70% of cases. Up to 4% of lung cancer patients present with SVCS at the time of diagnosis, and many more develop it at a later time. In younger patients with SVCS, lymphoma is commonly responsible. Recently, there has been a rise in benign SVCS secondary to the increased use of central venous catheters and pacemakers. Endovascular stenting of the SVC for SVCS has been described for more than 25 years and is now the first-line treatment of choice for benign and malignant SVCS. This chapter describes the use of the Endologix AFX AAA system for the treatment of SVCS.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.